Shenzhen Shenxin Biotechnology Co., Ltd

This study tests a new mRNA vaccine called IN006 to see if it is safe and helps the body fight RSV, a virus that can cause serious breathing problems. About 200 healthy adults, both younger (18-59) and older (60-79), will receive one or two shots of the vaccine or a placebo. Rese…

This phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants …